ATE337301T1 - Substituierte imide als tnf inhibitoren - Google Patents

Substituierte imide als tnf inhibitoren

Info

Publication number
ATE337301T1
ATE337301T1 AT95940847T AT95940847T ATE337301T1 AT E337301 T1 ATE337301 T1 AT E337301T1 AT 95940847 T AT95940847 T AT 95940847T AT 95940847 T AT95940847 T AT 95940847T AT E337301 T1 ATE337301 T1 AT E337301T1
Authority
AT
Austria
Prior art keywords
tnf inhibitors
substituted imides
imides
inhibitors
substituted
Prior art date
Application number
AT95940847T
Other languages
English (en)
Inventor
George Muller
Mary Shire
David I Stirling
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Application granted granted Critical
Publication of ATE337301T1 publication Critical patent/ATE337301T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
AT95940847T 1994-12-30 1995-11-20 Substituierte imide als tnf inhibitoren ATE337301T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/366,679 US6429221B1 (en) 1994-12-30 1994-12-30 Substituted imides

Publications (1)

Publication Number Publication Date
ATE337301T1 true ATE337301T1 (de) 2006-09-15

Family

ID=23444039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95940847T ATE337301T1 (de) 1994-12-30 1995-11-20 Substituierte imide als tnf inhibitoren

Country Status (20)

Country Link
US (3) US6429221B1 (de)
EP (1) EP0800514B1 (de)
JP (1) JP4118329B2 (de)
KR (2) KR20040007729A (de)
AT (1) ATE337301T1 (de)
AU (1) AU709719B2 (de)
CA (1) CA2208671C (de)
CZ (1) CZ203697A3 (de)
DE (1) DE69535195T2 (de)
DK (1) DK0800514T3 (de)
ES (1) ES2271948T3 (de)
FI (1) FI972709A (de)
HK (1) HK1004674A1 (de)
HU (1) HUT77124A (de)
NZ (1) NZ297324A (de)
PL (1) PL185361B1 (de)
PT (1) PT800514E (de)
RU (1) RU2162078C2 (de)
SK (1) SK86897A3 (de)
WO (1) WO1996020926A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
EP0818439B1 (de) * 1996-07-02 1999-10-13 Nisshin Flour Milling Co., Ltd. Imid derivate
CZ299810B6 (cs) * 1996-08-12 2008-12-03 Celgene Corporation Substituovaná aromatická sloucenina a její použití pro snížení hladiny cytokinu
WO1998007421A1 (fr) * 1996-08-16 1998-02-26 Ishihara Sangyo Kaisha, Ltd. Composition medicinale
EP0933360A1 (de) 1997-12-22 1999-08-04 Pharmachemie B.V. Synthese von Beta-lactamen
ES2138561B1 (es) * 1998-04-17 2000-07-01 Univ Madrid Complutense Uso de los peptidos vip y pacap en el tratamiento del shock endotoxico en mamiferos.
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US8030343B2 (en) 2000-06-08 2011-10-04 Celgene Corporation Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
CA2439410C (en) 2001-02-27 2011-09-06 William D. Figg Analogs of thalidomide as potential angiogenesis inhibitors
US7893071B2 (en) * 2001-04-23 2011-02-22 University Of Virginia Patent Foundation Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic
MXPA04000134A (es) 2001-06-26 2005-06-06 Abgenix Inc Anticuerpos para ligandos de osteoprotegerina.
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
EP1556033A4 (de) * 2002-05-17 2006-05-31 Celgene Corp Verfahren und zusammensetzungen mit selektiven cytokin-hemmenden arzneimitteln zur behandlung und versorgung von krebs und anderen erkrankungen
US20100129363A1 (en) * 2002-05-17 2010-05-27 Zeldis Jerome B Methods and compositions using pde4 inhibitors for the treatment and management of cancers
CA2501936A1 (en) * 2002-10-15 2004-04-29 Celgene Corporation Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
US20040087558A1 (en) 2002-10-24 2004-05-06 Zeldis Jerome B. Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
US7776907B2 (en) * 2002-10-31 2010-08-17 Celgene Corporation Methods for the treatment and management of macular degeneration using cyclopropyl-N-{2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-3-oxoisoindoline-4-yl}carboxamide
MXPA05004777A (es) * 2002-11-06 2005-07-22 Celgene Corp Metodos de uso y composiciones que comprenden farmacos inhibidores selectivos de citocina para el tratamiento y el manejo de padecimientos mieloproliferativos.
CN1735412A (zh) 2002-11-06 2006-02-15 细胞基因公司 利用选择性细胞因子抑制药物治疗和控制癌症和其它疾病的方法和组合物
BR0316256A (pt) * 2002-11-18 2005-10-04 Celgene Corp Métodos de inibir a produção de tnf-alfa e a atividade de pde4, de tratar ou prevenir uma doença ou um distúrbio, de controlar os nìveis de camp em uma célula e de produzir um composto, composição farmacêutica e composto
AU2003294311B8 (en) * 2002-11-18 2008-06-05 Celgene Corporation Method of using and compositions comprising (+)-3-(3,4-dimethoxy-phenyl)-3-(1-oxo-1,3-dihydro-isoindol-2-yl)-propionamide
CA2511843C (en) * 2002-12-30 2012-04-24 Celgene Corporation Fluoroalkoxy-substituted 1,3-dihydro-isoindolyl compounds and their pharmaceutical uses
US20040175382A1 (en) * 2003-03-06 2004-09-09 Schafer Peter H. Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
WO2005028436A2 (en) 2003-09-17 2005-03-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Thalidomide analogs as tnf-alpha modulators
US20050142104A1 (en) * 2003-11-06 2005-06-30 Zeldis Jerome B. Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders
EP2065383A1 (de) 2003-11-19 2009-06-03 Signal Pharmaceuticals, Inc. Indazolverbindungen und Verwendungsverfahren davon als Proteinkinasehemmer
US7684506B2 (en) 2004-02-13 2010-03-23 Panasonic Corporation Transmitter apparatus, receiver apparatus, and wireless communication method
BRPI0418743A (pt) * 2004-04-14 2007-09-18 Celgene Corp métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
CA2563377A1 (en) * 2004-04-23 2005-11-03 Celgene Corporation Methods of using and compositions comprising pde4 modulators for the treatment and management of pulmonary hypertension
WO2006028963A2 (en) * 2004-09-03 2006-03-16 Celgene Corporation Substituted heterocyclic compounds and uses thereof
US20070190070A1 (en) * 2004-09-03 2007-08-16 Zeldis Jerome B Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
JP2008518924A (ja) * 2004-10-28 2008-06-05 セルジーン・コーポレーション 中枢神経系損傷の治療及び管理のためのｐｄｅ４モジュレータを使用する方法及び組成物
US20080138295A1 (en) * 2005-09-12 2008-06-12 Celgene Coporation Bechet's disease using cyclopropyl-N-carboxamide
MY160002A (en) 2009-02-10 2017-02-15 Celgene Corp Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
MX341050B (es) 2010-04-07 2016-08-05 Celgene Corp * Metodos para tratar infeccion viral respiratoria.
MX341896B (es) 2010-06-15 2016-09-07 Celgene Corp * Biomarcadores para el tratamiento de psoriasis.
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
US20170087129A1 (en) 2014-05-16 2017-03-30 Celgene Corporation Compositions and methods for the treatment of atherosclerotic cardiovascular diseases with pde4 modulators
US10682336B2 (en) 2015-10-21 2020-06-16 Amgen Inc. PDE4 modulators for treating and preventing immune reconstitution inflammatory syndrome (IRIS)

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) * 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) * 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4215114A (en) * 1976-11-12 1980-07-29 The Upjohn Company Analgesic N-[2-(furyl-methylamino and 2-thienylmethylamino)cycloaliphatic]be
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) * 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) * 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) * 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
JPH0625163A (ja) * 1992-07-03 1994-02-01 Ube Ind Ltd Ｎ−（ジメトキシベンジル）フタルイミド類およびその製造法
WO1994008976A1 (en) * 1992-10-08 1994-04-28 E.I. Du Pont De Nemours And Company Fungicidal and miticidal aminopyrimidines
US5591767A (en) * 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5541213A (en) * 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5605914A (en) * 1993-07-02 1997-02-25 Celgene Corporation Imides
US5463063A (en) * 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US5698579A (en) * 1993-07-02 1997-12-16 Celgene Corporation Cyclic amides
DK0924201T3 (da) * 1993-11-30 2002-05-21 Searle & Co Tricyclisk substitueret pyrazolylbenzensulfonamider og deres anvendelse som cyclooxygenase II-inhibitorer
IT1270594B (it) * 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5703098A (en) * 1994-12-30 1997-12-30 Celgene Corporation Immunotherapeutic imides/amides
US5801195A (en) * 1994-12-30 1998-09-01 Celgene Corporation Immunotherapeutic aryl amides
US5703092A (en) * 1995-04-18 1997-12-30 The Dupont Merck Pharmaceutical Company Hydroxamic acid compounds as metalloprotease and TNF inhibitors
US5728844A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic agents
US5728845A (en) * 1995-08-29 1998-03-17 Celgene Corporation Immunotherapeutic nitriles
US5658940A (en) * 1995-10-06 1997-08-19 Celgene Corporation Succinimide and maleimide cytokine inhibitors
US6281230B1 (en) * 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5798368A (en) * 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
ES2339425T3 (es) 1996-07-24 2010-05-20 Celgene Corporation 2-(2,6-dioxopiperidin-3-il)-ftalimidas y -1-oxoisoindolinas sustituidas y procedimiento para reducir los niveles de tnf-alfa.
US5635517B1 (en) * 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
CZ299810B6 (cs) * 1996-08-12 2008-12-03 Celgene Corporation Substituovaná aromatická sloucenina a její použití pro snížení hladiny cytokinu
CZ299873B6 (cs) 1997-07-31 2008-12-17 Celgene Corporation Derivát hydroxamové kyseliny a farmaceutický prostredek s jeho obsahem
US5874448A (en) * 1997-11-18 1999-02-23 Celgene Corporation Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
US5955476A (en) * 1997-11-18 1999-09-21 Celgene Corporation Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
SE9803710L (sv) 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
US6020358A (en) * 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
RU2001121987A (ru) * 1999-03-18 2004-02-27 Селджин Корпорейшн (Us) Замещенные 1-оксо- и 1,3-диоксоизоиндолины и их применение в фармацевтических композициях для снижения уровней воспалительных цитокинов
US6667316B1 (en) 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
US6699899B1 (en) 1999-12-21 2004-03-02 Celgene Corporation Substituted acylhydroxamic acids and method of reducing TNFα levels
US6326388B1 (en) * 1999-12-21 2001-12-04 Celgene Corporation Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof

Also Published As

Publication number Publication date
NZ297324A (en) 2000-03-27
KR100466838B1 (ko) 2005-09-02
RU2162078C2 (ru) 2001-01-20
PL321065A1 (en) 1997-11-24
ES2271948T3 (es) 2007-04-16
US20050090516A1 (en) 2005-04-28
AU4246396A (en) 1996-07-24
KR20040007729A (ko) 2004-01-24
US6844359B2 (en) 2005-01-18
DE69535195D1 (de) 2006-10-05
FI972709A (fi) 1997-08-29
WO1996020926A1 (en) 1996-07-11
US7329761B2 (en) 2008-02-12
US20020143027A1 (en) 2002-10-03
HUT77124A (hu) 1998-03-02
EP0800514B1 (de) 2006-08-23
KR980700968A (ko) 1998-04-30
CA2208671C (en) 2009-02-10
CA2208671A1 (en) 1996-07-11
DE69535195T2 (de) 2007-07-12
SK86897A3 (en) 1998-01-14
DK0800514T3 (da) 2006-12-27
HK1004674A1 (en) 1998-12-04
PL185361B1 (pl) 2003-04-30
PT800514E (pt) 2006-12-29
EP0800514A1 (de) 1997-10-15
JPH10511946A (ja) 1998-11-17
CZ203697A3 (en) 1997-11-12
JP4118329B2 (ja) 2008-07-16
US6429221B1 (en) 2002-08-06
FI972709A0 (fi) 1997-06-23
AU709719B2 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
ATE337301T1 (de) Substituierte imide als tnf inhibitoren
DE69522961D1 (en) Immunotherapeutische arylamide
PT862552E (pt) Succinimidas e maleimidas inibidoras de citocinas
ATE259787T1 (de) Inhibitoren des tumor-necrosis-factors
EP1004572A3 (de) Aminen als Inhibitoren von TNF alpha
NO996529D0 (no) Substituerte alkanohydroksamsyrer og metode for reduksjon av TNF<alfa>-nivåer
EA199700186A1 (ru) Новые дипептидные амидины, используемые в качестве ингибиторов тромбина
WO1998024763A3 (en) Immunotherapeutic imides/amides as pde iv and tnf inhibitors
NO986103L (no) Substituerte indazol-derivater og deres anvendelse som fosfodiesterase (PDE)type IV - og tumornekrose-faktor (TNF)inhibitorer
ATE114467T1 (de) (+)-alpha-(2,3 dimethoxyphenyl)-1-(2- (fluorophenyl)ethyl>-4-piperidinmethanol.
DK0726899T3 (da) Nye pyrazincarboxamidderivater, deres fremstilling og deres anvendelse i lægemidler
NO953763L (no) Heterocykel-holdige amidin-derivater, deres fremstilling og anvendelse
DK0797437T3 (da) Immunterapeutiske imider/amider samt anvendelse deraf til at reducere niveauer af TNFalfa
GB8926611D0 (en) Compound and its use
EA200200331A1 (ru) Применение лептина для ингибирования пролиферации эндотелиальных клеток
DK1308444T3 (da) Substitueret 2(2,6 dioxo-3-fluorpiperidin-3-yl)-isoindoliner og deres anvendelse til reduktion af TNFalfa-niveau'er

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0800514

Country of ref document: EP

REN Ceased due to non-payment of the annual fee